Gene

STK11

serine/threonine kinase 11

Explore in graph →CI-GENE-00034062HGNC:11389 ENSG00000118046 NCBI 6794 CIViC Cancer geneApproved

Curated evidence

Clinical evidence (28)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–28 of 28 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
STK11 D194E1
Everolimus	Malignant Pancreatic Neoplasm	Predictive	C	Supports Sensitivity Response	2	accepted	EID1617 Case study of a 46-year old male patient with Peutz-Jeghers Syndrome and pancreatic cancer. A germline STK11 D194E mutation was identified with LOH in the tumor sample. phospho-S6 ribosomal protein st…

Cohorts

Alteration frequency by cohort (99)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved99 cohort rows (showing 49, sorted by frequency) · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Bladder Cancer (MSK, Nat Genet 2016) blca_plasmacytoid_mskcc_2016	Bladder Urothelial Carcinoma	Ssm

Literature

Linked publications (12)

25 per page, newest first.

pubmedPublishedShowing 1–12 of 12 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Different prognostic impact of STK11 mutations in non-squamous non-small-cell lung cancer.
· Oncotarget · 2017 · PMID 26625312 · validated civic_curation pubmed
Disease pattern in Danish patients with Peutz-Jeghers syndrome.
· Int J Colorectal Dis · 2016 · PMID 26979979 · validated civic_curation pubmed
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.
· Cancer Discov · 2018 · PMID 29773717 · validated civic_curation pubmed
Further observations on LKB1/STK11 status and cancer risk in Peutz-Jeghers syndrome.
· Br J Cancer · 2003 · PMID 12865922 · validated civic_curation pubmed

STK11 EXON 1-2 MUTATION1
(prognostic)	Lung Non-Small Cell CarcinomaCURATED_BROADER	Prognostic	B	Supports Poor Outcome	4	accepted	EID750 In a retrospective analysis of 567 non-squamous, non-small cell lung cancer patients, Exon 1-2 mutations in STK11 were significantly associated with shorter OS (24 vs. 69 months) also after multivaria… (full text at CIViC) PMID 26625312 · Pécuchet et al., 2017 · Open in CIViC	civic

STK11 EXON 1-2 MUTATION1

(prognostic)

Lung Non-Small Cell CarcinomaCURATED_BROADER

Prognostic

Supports Poor Outcome

accepted

EID750

In a retrospective analysis of 567 non-squamous, non-small cell lung cancer patients, Exon 1-2 mutations in STK11 were significantly associated with shorter OS (24 vs. 69 months) also after multivaria… (full text at CIViC)

PMID 26625312 · Pécuchet et al., 2017 · Open in CIViC

STK11 Loss6
(predisposing)	Peutz-Jeghers SyndromeUNRESOLVED	Predisposing	B	Supports Predisposition	3	accepted	EID1737 In a series of 33 patients with Peutz-Jeghers Syndrome, 17 mutations in STK11/LKB1 were observed in exons 1-8 (none in exon 9). 11 of these mutations were predicted to be truncating. These mutations o… (full text at CIViC) PMID 12865922 · Lim et al., 2003 · Open in CIViC	civic
Docetaxel + SelumetinibCombination	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	D	Supports Resistance	3	accepted	EID1144 A clinical trial comparing selumetinib and docetaxel vs. docetaxel and placebo in KRAS mutant NSCLC was recapitulated in mice. Tumors were induced in lung epithelium by nasal instillation of CRE-beari… (full text at CIViC) PMID 22425996 · Chen et al., 2012 · Open in CIViC	civic
Everolimus + SirolimusSubstitutes	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	D	Does Not Support Sensitivity Response	3	accepted	EID1620 Preclinical study in 5 NSCLC cell lines. Two LKB1 (STK11) mutant cell lines had higher basal levels of mTOR activity (pS6K and p4EBP1 levels) but were not more sensitive to mTOR inhibitors (everolimus… (full text at CIViC) PMID 26027660 · Xiao et al., 2015 · Open in CIViC	civic
Roflumilast	Pancreatic Ductal Adenocarcinoma	Predictive	D	Supports Sensitivity Response	2	accepted	EID12555 In a preclinical study using STK11/LKB1-deficient pancreatic ductal adenocarcinoma (PDAC) cell lines (TB 32047, PANC-1, SUIT2, SU86.86, KPC792) and C57BL/6 orthotopic mouse models (n = 5 per group), t… (full text at CIViC) PMID 38461159 · Zhang et al., 2024 · Open in CIViC	civic
Sirolimus	Peutz-Jeghers SyndromeUNRESOLVED	Predictive	D	Supports Sensitivity Response	1	accepted	EID1618 Preclinical study in a mouse model of Peutz-Jeghers syndrome. Heterozygous Lkb1 (STK11) knockout mice were generated and treated with rapamycin after the onset of polyposis at 9 months of age. Rapamyc… (full text at CIViC) PMID 18281551 · Wei et al., 2008 · Open in CIViC	civic
〃	Peutz-Jeghers SyndromeUNRESOLVED	Predictive	D	Supports Sensitivity Response	1	accepted	EID1619 Treatment of mice with a heterozygous loss of Lkb1 (STK11) with rapamycin led to reduction in polyp size (p < 0.0001) and number of polyps (p=0.00022). pS6 staining was also reduced after rapamycin tr… (full text at CIViC) PMID 19541609 · Shackelford et al., 2009 · Open in CIViC	civic

STK11 Loss10
MEK Inhibitor CI-1040	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	—	rejected	EID2319 STK11 is mutated and inactivated in 20-30% of non-small cell lung cancers, most often in the adenocarcinoma subtype. PMID 15021901 · Carretero et al., 2004 · Open in CIViC	civic
〃	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	—	rejected	EID2320 STK11 is mutated and inactivated in 20-30% of non-small cell lung cancers, most often in the adenocarcinoma subtype. PMID 21102257 · Marcus et al., 2010 · Open in CIViC	civic
〃	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	—	rejected	EID2321 STK11 is mutated and inactivated in 20-30% of non-small cell lung cancers, most often in the adenocarcinoma subtype. PMID 12097271 · Sanchez-Cespedes et al., 2002 · Open in CIViC	civic
〃	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	—	rejected	EID2322 STK11 is mutated and inactivated in 20-30% of non-small cell lung cancers, most often in the adenocarcinoma subtype. PMID 18948947 · Ding et al., 2008 · Open in CIViC	civic
〃	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	D	Supports Sensitivity Response	—	submitted	EID2318 NSCLC cell lines that contain inactivating STK11 mutations and activating KRAS mutations have shown a reduced proliferation rate in response to the MEK inhibitor CI-1040 (P<0.001) compared to NSCLC ce… (full text at CIViC) PMID 19165201 · Mahoney et al., 2009 · Open in CIViC	civic
Sirolimus	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	—	submitted	EID2314 STK11 is mutated and inactivated in 20-30% of non-small cell lung cancers, most often in the adenocarcinoma subtype. PMID 15021901 · Carretero et al., 2004 · Open in CIViC	civic
〃	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	—	rejected	EID2315 STK11 is mutated and inactivated in 20-30% of non-small cell lung cancers, most often in the adenocarcinoma subtype. PMID 21102257 · Marcus et al., 2010 · Open in CIViC	civic
〃	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	—	submitted	EID2316 STK11 is mutated and inactivated in 20-30% of non-small cell lung cancers, most often in the adenocarcinoma subtype. PMID 12097271 · Sanchez-Cespedes et al., 2002 · Open in CIViC	civic
〃	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	—	submitted	EID2317 STK11 is mutated and inactivated in 20-30% of non-small cell lung cancers, most often in the adenocarcinoma subtype. PMID 18948947 · Ding et al., 2008 · Open in CIViC	civic
〃	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	D	Supports Sensitivity Response	—	submitted	EID2313 NSCLC cell lines that contain inactivating STK11 mutations and activating KRAS mutations have shown a reduced proliferation rate in response to the MEK inhibitor CI-1040 (P<0.001) compared to NSCLC ce… (full text at CIViC) PMID 19165201 · Mahoney et al., 2009 · Open in CIViC	civic